Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Ruwen Yang, Jingyu Shang, Yaru Zhou, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 12, pp. 1401-1409
Closed Access | Times Cited: 25

Showing 25 citing articles:

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 87
Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Youwen Pan, Yafang Yang, Jiale Wu, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials
Ehsan Amini‐Salehi, Sandeep Samethadka Nayak, Gautam Maddineni, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 5, pp. 2900-2910
Open Access | Times Cited: 8
The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review
Azin Vakilpour, Ehsan Amini‐Salehi, Arman Soltani Moghadam, et al.
Nutrition and Diabetes (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?
Anna Gudan, Katarzyna Kozłowska‐Petriczko, Ewa Wunsch, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1323-1323
Open Access | Times Cited: 21
Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study
Amirhossein Naghipour, Ehsan Amini‐Salehi, Mahdi Orang Gorabzarmakhi, et al.
Systematic Reviews (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
Ehsan Amini‐Salehi, Soheil Hassanipour, Mohammad‐Hossein Keivanlou, et al.
Nutrition Reviews (2023) Vol. 82, Iss. 6, pp. 815-830
Closed Access | Times Cited: 17
Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
Alejandra Mijangos-Trejo, Natalia Nuño‐Lámbarri, Varenka J. Barbero-Becerra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14918-14918
Open Access | Times Cited: 17
An umbrella review of meta-analyses on the effects of microbial therapy in metabolic dysfunction-associated steatotic liver disease
Yuanyue Yao, Qing Hong, Siqi Ding, et al.
Clinical Nutrition (2025) Vol. 47, pp. 1-13
Closed Access
Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses
Abinash Mahapatro, Fnu Bawna, Vikash Kumar, et al.
Clinical Nutrition ESPEN (2023) Vol. 57, pp. 475-486
Closed Access | Times Cited: 15
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
Xiang Zhang, Harry Cheuk-Hay Lau, Jun Yu
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100018-100018
Open Access
Gut microbiome in non-alcoholic fatty liver disease
Anastasios Mpountouridis, Christina Tsigalou, Ioanna Bezirtzoglou, et al.
Frontiers in Gastroenterology (2025) Vol. 3
Open Access
The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials
Wenmin Xing, Wenyan Gao, Xiaoling Lv, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 18
The immune response as a therapeutic target in non-alcoholic fatty liver disease
Nicolás Ortiz‐López, Catalina Fuenzalida, María Soledad Dufeu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges
Robert Hegarty, Eirini Kyrana, Emer Fitzpatrick, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 9
Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
Qiuhong Wang, Ze Wang, Boxian Pang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 11
Promoting longevity in aged liver through NLRP3 inflammasome inhibition using tauroursodeoxycholic acid (TUDCA) and SCD probiotics
Burcu Baba, Taha Ceylani, Rafig Gurbanov, et al.
Archives of Gerontology and Geriatrics (2024) Vol. 125, pp. 105517-105517
Open Access | Times Cited: 1
Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials
Wu Juan, Xiaoyang Chen, Jun Qian, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102397-102397
Closed Access | Times Cited: 1
Probiotics’ effect on visceral and subcutaneous adipose tissue: a systematic review of randomized controlled trials
Leonardo M. Porchia, Gabriela Vazquez-Marroquin, Renata Ochoa-Précoma, et al.
European Journal of Clinical Nutrition (2022) Vol. 76, Iss. 12, pp. 1646-1656
Closed Access | Times Cited: 7
MAFLD under the lens: the role of gut microbiota
P.C. Sousa, Mariana Verdelho Machado
Metabolism and Target Organ Damage (2022) Vol. 2, Iss. 4, pp. 14-14
Open Access | Times Cited: 3
Promoting Longevity in Aged Liver through NLRP3 Inflammasome Inhibition Using Tauroursodeoxycholic Acid (TUDCA) and SCD Probiotics
Burcu Baba, Taha Ceylani, Eda Açıkgöz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Probiotics as a targeted intervention in anti-aging: A review
Fengcui Shi, Ji Peng, Hongmin Li, et al.
Biomarkers (2024), pp. 1-9
Closed Access
The role of probiotics in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): new insights based on meta-analysis and subgroup analysis
M. Xiao, Yang Cao, Linlin Wang, et al.
Food Bioscience (2024) Vol. 62, pp. 105454-105454
Closed Access
The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
Gautam Maddineni, Sri J. Obulareddy, Ruchir Paladiya, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 8, pp. 4714-4731
Open Access
Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review
Dominik Strikić, Andro Vujević, Dražen Perica, et al.
Diabetology (2023) Vol. 4, Iss. 4, pp. 538-552
Open Access
Page 1

Scroll to top